CVRx (NASDAQ: CVRX) — Company Overview, News & Financial Data
CVRx specializes in innovative treatments for heart failure, focusing on improving quality of life using the Barostim NEO™ therapy.
CVRx
CVRx (NASDAQ:CVRX) specializes in developing and commercializing innovative treatments for heart failure and related cardiovascular diseases. Their notable project, the Barostim NEO™, is a pioneering therapy that aims to improve the quality of life for people suffering from heart failure by using neuromodulation technology. Operating primarily in the healthcare sector, CVRx's objective is to address the unmet needs of patients through cutting-edge solutions, contributing to advancements in cardiovascular health. Their focus extends to ongoing research and development activities, aiming to expand their portfolio and deliver meaningful improvements in patient care around the globe.
Snapshot
Operations
Products and/or services of CVRx
- Barostim Therapy offers innovative heart failure and resistant hypertension treatment through neuromodulation.
- Barostim NEO System, an advanced device designed for the safe and effective delivery of Barostim Therapy.
- Clinical trials on Barostim's effectiveness in heart failure treatment, aiming to expand its therapeutic indications.
- Research collaborations to explore Barostim Therapy's potential in other cardiovascular conditions.
- Educational programs for healthcare professionals to facilitate Barostim Therapy adoption.
- Patient support initiatives to ensure accessibility and compliance with Barostim Therapy.
CVRx executive team
- Kevin HykesPresident, CEO & Director
- Philip B. AdamsonChief Medical Officer